TENAX THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
TENAX THERAPEUTICS, INC. (TENX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-08-11
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $333.78K.
- TENAX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $333.78K 10-K · filed 2022-03-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $333.78K 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $333.78K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $0.00 10-K · filed 2022-03-29 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |